$ULTA

Cap Stock Picks Poised to Rally in the 2nd Half, According to BofA

BofA analyst Carey Hall said Ulta could rebound in 2H26, keeping a $685 price target despite the stock down 20% YTD on weaker consumer demand. BofA also backed elf Beauty ($85 target) and Wayfair, citing easing supply-chain pressures. It maintained bullish targets for Charles River ($220), Dynatrace, MKS ($2H26 top idea), EastGroup, and Samsara.

Original reporting
Published Jun 26, 2026, 6:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 26, 2026, 6:57 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cap Stock Picks Poised to Rally in the 2nd Half, According to BofA — source image
Decision brief

The 30-second read

$ULTABullishLow
01

Why it matters

Because the piece is primarily analyst commentary (targets and narratives) rather than new company disclosures, it is more useful for relative positioning and sentiment than for a fresh fundamental catalyst.

02

Market read

Traders may use the note to adjust relative exposure to the named turnaround/growth stories, but it likely won’t drive a major repricing without new prints.

03

What to watch

Execution risk and timing: turnaround/normalization stories (ULTA/W/EGP) and AI infrastructure demand read-through (DT/MKSI/IOT) can slip if macro conditions or customer capex cycles change.

Relevance 4/10Novelty 3/10Timing: for 2H26 positioning based on BofA’s maintained bullish targets

Background

The article summarizes BofA’s small/mid-cap “cap stock picks” and provides maintained price targets and qualitative theses across multiple companies.

Company-level read

Ticker impact

$ULTABullishMedium confidence
Context

BofA reiterates a bullish view on Ulta, citing a “turnaround is imminent” thesis and maintaining a $685 price target.

Expected impact

Mild upside bias versus peers if traders treat the note as a catalyst; otherwise limited incremental impact.

Evidence & confidence

The article is an analyst call with targets and qualitative rationale, not a fresh earnings/guidance print or operational disclosure.

$ELFBullishMedium confidence
Context

BofA keeps a bullish stance on elf Beauty, maintaining an $85 price target and pointing to margin expansion and tariff rebound benefits.

Expected impact

Moderate sentiment support; likely more relevant for relative-value trades than for a major repricing.

Evidence & confidence

No new financial results are provided—only a maintained target and macro/operational narrative.

$WBullishMedium confidence
Context

BofA sees Wayfair as a likely winner as supply-chain pressures ease, while noting margins near the lower end of its long-term EBITDA range.

Expected impact

Potential modest rebound in sentiment if investors buy into the normalization timing; not a hard catalyst.

Evidence & confidence

The article provides qualitative guidance on what BofA expects, but no new Wayfair-specific print or contract.

$CRLBullishMedium confidence
Context

BofA maintains a bullish view on Charles River Laboratories, keeping a $220 price target despite biotech spending declines.

Expected impact

Limited incremental impact unless traders were underweight on the name; more supportive than directional.

Evidence & confidence

This is target-based commentary without new CRL disclosures.

$DTBullishMedium confidence
Context

BofA highlights Dynatrace as an “industry disruptor,” citing improving fundamentals and AI/digital modernization driving observability usage.

Expected impact

Potential positive bias for growth/AI infrastructure trades; likely gradual rather than immediate repricing.

Evidence & confidence

No new product metrics, bookings, or guidance are disclosed—only an analyst narrative.

$MKSIBullishMedium confidence
Context

BofA names MKS Instruments as its top 2H26 SMID cap idea, expecting WFE capacity expansions and tech upgrades to support AI infrastructure demand.

Expected impact

More likely to influence medium-term positioning than to trigger a near-term fundamental repricing.

Evidence & confidence

The article is a forward-looking analyst thesis with no new MKSI order/backlog or guidance datapoint.

$EGPBullishMedium confidence
Context

BofA stays bullish on EastGroup, citing high demand in the US Sunbelt and ongoing data center buildout support.

Expected impact

Potential modest support for the stock/sector relative to industrial REIT peers if the market buys the tailwind timing.

Evidence & confidence

No new leasing/occupancy or guidance figures are provided—this is primarily an analyst outlook.

$IOTBullishMedium confidence
Context

BofA frames Samsara as a turnaround/growth story, arguing competitive advantages are widening via data scale and platform breadth.

Expected impact

Could help sentiment and reduce perceived downside, but likely not a major catalyst absent new results.

Evidence & confidence

The article provides qualitative competitive claims and expectations rather than fresh company disclosures.

Market effects

Broadly bullish read-through on consumer discretionary retail turnaround (ULTA/ELF), e-commerce normalization (W), and AI infrastructure/observability/industrial tech demand narratives (DT/MKSI/IOT).

EastGroup’s Sunbelt industrial demand framing may reinforce regional industrial REIT sentiment.

Tariff rebound and supply-chain easing assumptions are macro inputs that can affect multiple discretionary and industrial/tech demand expectations.

Counterpoint

These are analyst thesis pieces with maintained targets; without new earnings, guidance, or hard datapoints, the market may already be pricing the turnaround narratives.

Key entities

  • BofA

    Provides bullish price targets and turnaround/growth theses for multiple stocks discussed in the article.

  • Carey Hall

    The named BofA analyst whose written rationale is quoted for several of the picks.

Related articles

$ULTAMedAI 9/10

Ulta Beauty earnings analysis: questions answered and next catalysts

Ulta Beauty (ULTA) reported Q2 earnings exceeding estimates, with EPS at $6.55 and revenue at $3.00B, but shares fell 4% due to concerns about H2 growth. The company showed market share gains, SG&A leverage, and accelerated capital returns. Despite raising FY guidance, the market is cautious about margin recovery and H2 risks. Key catalysts include Q3 earnings, holiday season performance, and SG&A leverage proof.

$ULTAMedAI 8/10

Ulta Beauty stock drops despite strong results: Add to watchlist or buy today?

Ulta Beauty (ULTA) shares fell 5.45% to $510.64 despite beating Q2 earnings estimates, with EPS at $6.55 and revenue at $3.00B. Comparable sales slowed to 3.8% from 6.7% YoY, and guidance for H2 comps is 2-3%. The company raised FY EPS guidance to $28.70-$29.00 and expanded its buyback program. Analysts remain bullish with an average price target of ~$670, but the stock has underperformed due to deceleration concerns.

$MRVLMed

Wall St set for subdued open as tech rally pauses before Warsh's speech

Wall Street set for a muted open as tech rally pauses ahead of Fed Chair Kevin Warsh's speech. Nvidia, Micron, and Intel saw premarket declines, while PayPal dropped 14.4% after a reported abandoned buyout. Gap rose 17.4% on new CEO and profit forecast. Investors await economic data and Fed commentary for rate hike clues.